Agios Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 15, 2025. Live webcast available.
Quiver AI Summary
Agios Pharmaceuticals, Inc. has announced that its management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET. The presentation will be available via live webcast on the Agios website, with a replay archived for at least two weeks thereafter. Agios specializes in developing therapies for rare diseases, particularly focusing on pyruvate kinase activation. The company markets a first-in-class treatment for adults with PK deficiency and is advancing a clinical pipeline that includes therapies for various hematologic diseases. They are also exploring a preclinical treatment for polycythemia vera. For more information, the press release encourages visiting their website.
Potential Positives
- Agios Pharmaceuticals will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, enhancing its visibility and credibility within the healthcare investment community.
- The company is a leader in cellular metabolism and PK activation, showcasing its innovative approach to treating rare diseases, which may attract interest from investors and collaborators.
- Agios is actively advancing a robust clinical pipeline with multiple investigational medicines targeting various rare hematologic diseases, indicating strong growth potential and commitment to innovation.
- Agios markets a first-in-class therapy for PK deficiency, reinforcing its position as a pioneer in developing disease-modifying treatments for rare diseases.
Potential Negatives
- None
FAQ
When is Agios Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?
Agios Pharmaceuticals will present on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
Where can I watch the Agios presentation?
The presentation will be accessible via a live webcast on Agios' website under the "Events & Presentations" tab.
How long will the webcast replay be available?
The webcast replay will be archived on Agios' website for at least two weeks following the presentation.
What therapies is Agios currently developing?
Agios is developing therapies for rare diseases, including programs in thalassemia, sickle cell disease, and phenylketonuria.
What is the focus of Agios Pharmaceuticals?
Agios focuses on cellular metabolism and PK activation to develop transformative therapies for patients with rare diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AGIO Insider Trading Activity
$AGIO insiders have traded $AGIO stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by insiders over the last 6 months:
- DAVID SCADDEN sold 200 shares.
- RAHUL D. BALLAL has traded it 5 times. They made 0 purchases and 5 sales, selling 20,000 shares.
- JAMES WILLIAM BURNS (Chief Legal Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 21,752 shares.
- CECILIA JONES (Chief Financial Officer) sold 2,542 shares.
- BRIAN GOFF (Chief Executive Officer) sold 11,091 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AGIO Hedge Fund Activity
We have seen 102 institutional investors add shares of $AGIO stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POLAR CAPITAL HOLDINGS PLC added 1,002,036 shares (+inf%) to their portfolio in Q3 2024
- VESTAL POINT CAPITAL, LP added 760,000 shares (+inf%) to their portfolio in Q3 2024
- DIMENSIONAL FUND ADVISORS LP removed 633,902 shares (-28.9%) from their portfolio in Q3 2024
- SCHONFELD STRATEGIC ADVISORS LLC removed 433,099 shares (-93.3%) from their portfolio in Q3 2024
- ROCK SPRINGS CAPITAL MANAGEMENT LP removed 344,872 shares (-33.0%) from their portfolio in Q3 2024
- LAURION CAPITAL MANAGEMENT LP removed 248,395 shares (-100.0%) from their portfolio in Q3 2024
- MORGAN STANLEY removed 247,702 shares (-41.5%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 43
rd
Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
The live webcast will be accessible on the Investors section of the company's website (
www.agios.com
) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at
www.agios.com
.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
